SUCCESSFUL CO-TREATMENT OF BCR-ABL LEUKEMIC CELLS WITH PONATINIB, AN ABL KINASE INHIBITOR, AND VORINOSTAT, A HISTONE DEACETYLASE INHIBITOR: A POTENTIAL TREATMENT FOR BCR-ABL POSITIVE LEUKEMIA CELLS

被引：0
|
作者：
Okabe, S. [1 ]
Tauchi, T. [1 ]
Kimura, S. [2 ]
Maekawa, T. [3 ]
Ohyashiki, K. [1 ]
机构：
[1] Tokyo Med Univ, Tokyo, Japan
[2] Saga Univ, Saga, Japan
[3] Kyoto Univ Hosp, Kyoto, Japan
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0521
引用
收藏
页码：210 / 210
页数：1
相关论文
共 50 条
  • [21] Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib
    Tanaka, C.
    Yin, O. Q. P.
    Sethuraman, V.
    Smith, T.
    Wang, X.
    Grouss, K.
    Kantarjian, H.
    Giles, F.
    Ottmann, O. G.
    Galitz, L.
    Schran, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (02) : 197 - 203
  • [22] The effect of cerivastatin on BCR-ABL positive cells.
    Kuhn, C
    Metzgeroth, G
    La Rosèe, P
    Hastka, J
    Hochhaus, A
    Hehlmann, R
    Willer, A
    BLOOD, 2002, 100 (11) : 788A - 788A
  • [23] EXPRESSION OF BCR AND BCR-ABL FUSION TRANSCRIPTS IN NORMAL AND LEUKEMIC-CELLS
    COLLINS, S
    COLEMAN, H
    GROUDINE, M
    MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (08) : 2870 - 2876
  • [24] Non-tyrosine kinase inhibitor-targeting of BCR-ABL expressing cells
    Frankfurt, Olga
    Platanias, Leonidas C.
    LEUKEMIA & LYMPHOMA, 2012, 53 (10) : 1857 - 1858
  • [25] Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins
    Skourides, PA
    Perera, SA
    Ren, RB
    ONCOGENE, 1999, 18 (05) : 1165 - 1176
  • [26] Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins
    Paris A Skourides
    Samanthi A Perera
    Ruibao Ren
    Oncogene, 1999, 18 : 1165 - 1176
  • [27] Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant Bcr-Abl positive lymphoid malignancies
    Ottmann, OG
    Giles, FJ
    Wassmann, B
    Wunderle, L
    Bhalla, K
    Jones, D
    Hochhaus, A
    Rae, PE
    Mietlowski, W
    Beran, M
    Albitar, M
    Alland, L
    Dugan, M
    Kantarjian, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 22 - 22
  • [28] Effects of an ABL-protein kinase inhibitor on the growth BCR-ABL positive lymphoblastic leukemias in vitro.
    Ottmann, OG
    Ballas, K
    Brauns, T
    Kalina, U
    Fauth, F
    Atta, J
    Martin, H
    Buchdunger, E
    Hoelzer, D
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 210 - 210
  • [29] Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
    Bucur, Octavian
    Stancu, Andreea Lucia
    Goganau, Ioana
    Petrescu, Stefana Maria
    Pennarun, Bodvael
    Bertomeu, Thierry
    Dewar, Rajan
    Khosravi-Far, Roya
    PLOS ONE, 2013, 8 (10):
  • [30] Efficacy of an Abl tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents against Bcr-Abl positive cells.
    Thiesing, JT
    Ohno-Jones, S
    Kolibaba, KS
    Druker, BJ
    BLOOD, 1999, 94 (10) : 100A - 101A
12345